Miacalcic

Calcitonin salmon, synthetic, the active ingredient in Miacalcic, is a calcitonin presented as an injectable solution for intramuscular, intravenous, and subcutaneous use. It lowers elevated blood calcium and modulates bone turnover in conditions such as hypercalcemia, Paget's disease of bone, and osteoporosis.

GNH USA supplies Miacalcic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring EU‑standard quality and reliable global distribution.

Miacalcic acts on calcium metabolism and bone remodeling pathways, providing therapeutic benefit in several bone‑related disorders.

Hypercalcemia: reduces serum calcium levels, helping to normalize calcium balance. Paget's disease of bone: moderates abnormal bone remodeling and alleviates associated pain. Osteoporosis: decreases bone resorption, contributing to reduced risk of vertebral fractures.

Miacalcic may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: transient feeling of sickness. - Flushing: warm sensation and reddening of the skin. - Headache: mild to moderate intensity. - Injection site reactions: pain, erythema, or swelling. - Dizziness: occasional light‑headedness. - Mild hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Severe hypocalcemia: marked reduction in blood calcium requiring medical intervention. - Anaphylaxis: life‑threatening allergic reaction with rash, swelling, and respiratory distress. - Significant hypotension: profound blood pressure drop that may cause fainting. - Persistent vomiting: prolonged emesis leading to dehydration.

When prescribing Miacalcic, clinicians should consider several precautionary measures to ensure patient safety.

Renal impairment: monitor calcium and renal function closely. Hypersensitivity history: avoid use in patients with known allergy to salmon calcitonin. Pregnancy: use only if potential benefit outweighs unknown risk. Concurrent calcium‑lowering agents: adjust therapy and monitor serum calcium. Severe hypertension: observe blood pressure during administration. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Miacalcic can interact with other medicines that affect calcium balance or bone metabolism.

Major Interactions (Avoid): - Calcium supplements: may diminish calcitonin efficacy. - Bisphosphonates: additive calcium‑lowering effect increasing hypocalcemia risk. - Loop diuretics: potentiate calcium loss, requiring close monitoring.

Moderate Interactions (Monitor Closely): - Vitamin D analogues: may alter calcium homeostasis, necessitate serum monitoring. - Corticosteroids: influence bone turnover, adjust treatment as needed. - Thiazide diuretics: can counteract calcium reduction, watch serum levels.